Clarivate Analytics pegged 11 drugs set to enter the market during 2020 as potential blockbusters by 2024
The U.S. Food and Drug Administration approved Roche/Genentech’s Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in pediatric patients 2 years of age and older.
Cambridge, Mass.-based bluebird bio’s LentiGlobin gene therapy is increasing hemoglobin levels in anemia patients battling sickle cell disease and beta thalassemia, which reduces the need for blood transfusions in those patients.
bluebird bio’s interim data for its Phase III gene therapy LentiGlobin trial showed promising results in reducing a patient’s need for blood transfusions after one month after treatment, but the data also raised some concerns.
U.S. health regulators are under increasing pressure to remove restrictions keeping most gay and bisexual men from donating blood, but experts say any change would require years of research to guarantee the safety of the blood supply. The U.S. Food and Drug Administration enacted a lifetime ban for gay and bisexual men in the 1980s […]
CAMBRIDGE, Mass. — Stocks for bluebird bio (BLUE) slid 6.5 percent Monday after the company revealed a patient who underwent an early gene study treatment for beta-thalassemia seven years ago required new treatments following a relapse. Marina Cavazzana, a professor of hematology and lead investigator for bluebird’s HGB-205 clinical study, said the patient she […]